Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 10, Pages 1167-1179
Publisher
Informa UK Limited
Online
2016-08-12
DOI
10.1080/13543784.2016.1221925
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GLP-1 and weight loss: unraveling the diverse neural circuitry
- (2016) Scott E. Kanoski et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- News and Views
- (2016) Iskandar Idris DIABETES OBESITY & METABOLISM
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
- (2016) Olivia M. Farr et al. DIABETOLOGIA
- Dulaglutide (LY-2189265) for the treatment of type 2 diabetes
- (2016) André J. Scheen Expert Review of Clinical Pharmacology
- Role of Genetic Variation in the Cannabinoid Receptor Gene (CNR1) (G1359A Polymorphism) on Weight Loss and Cardiovascular Risk Factors After Liraglutide Treatment in Obese Patients With Diabetes Mellitus Type 2
- (2016) Daniel Antonio de Luis et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review
- (2016) Lin Zhang et al. Scientific Reports
- Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points
- (2015) Daisuke Yabe et al. CURRENT MEDICAL RESEARCH AND OPINION
- Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
- (2015) Luc Van Gaal et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From aDiabetes CareEditors’ Expert Forum
- (2015) William T. Cefalu et al. DIABETES CARE
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes
- (2015) Laurence G. Trahair et al. DIABETOLOGIA
- Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
- (2015) Ele Ferrannini et al. EUROPEAN HEART JOURNAL
- Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study
- (2015) Mojca Jensterle et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy
- (2015) Andreas Brønden et al. Expert Opinion on Drug Metabolism & Toxicology
- Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications
- (2015) Bruno Halpern et al. Expert Opinion On Drug Safety
- An overview of new GLP-1 receptor agonists for type 2 diabetes
- (2015) Brian Tomlinson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Liraglutide—another weapon in the war against obesity?
- (2015) George A. Bray Nature Reviews Endocrinology
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
- (2015) Miles Fisher et al. Lancet Diabetes & Endocrinology
- Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness
- (2015) Sarah L. Anderson et al. Therapeutic Advances in Chronic Disease
- Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes
- (2014) Mitchel Tate et al. BRITISH JOURNAL OF PHARMACOLOGY
- Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus
- (2014) Nathaniel R. Smilowitz et al. CIRCULATION
- Cardiovascular Actions of Incretin-Based Therapies
- (2014) John R. Ussher et al. CIRCULATION RESEARCH
- Incretin Therapy and Pancreatic Pathologies: Background Pathology Versus Drug-Induced Pathology in Rats
- (2014) J. M. Egan et al. DIABETES
- Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials
- (2014) Matteo Monami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Dulaglutide: First Global Approval
- (2014) Mark Sanford DRUGS
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
- (2014) Asger Lund et al. European Journal of Internal Medicine
- Potential side effects to GLP-1 agonists: understanding their safety and tolerability
- (2014) Agostino Consoli et al. Expert Opinion On Drug Safety
- Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
- (2014) Cynthia L. Ogden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
- (2014) Laurie L. Baggio et al. JOURNAL OF CLINICAL INVESTIGATION
- Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
- (2014) Stephanie Sisley et al. JOURNAL OF CLINICAL INVESTIGATION
- Relation of the rs6923761 Gene Variant in Glucagon-Like Peptide 1 Receptor with Weight, Cardiovascular Risk Factor, and Serum Adipokine Levels in Obese Female Subjects
- (2014) Daniel Antonio de Luis et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes
- (2014) Robert R. Henry et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Combination phentermine and topiramate for weight maintenance: the first Australian experience
- (2014) Sandra L Neoh et al. MEDICAL JOURNAL OF AUSTRALIA
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
- (2014) Assumpta Caixas et al. Drug Design Development and Therapy
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- GLP-1 receptor agonists: a review of head-to-head clinical studies
- (2014) Jennifer M. Trujillo et al. Therapeutic Advances in Endocrinology and Metabolism
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- (2013) M E J Lean et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6
- (2013) R. Shirazi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Is there a place for incretin therapies in obesity and prediabetes?
- (2013) Jens Juul Holst et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
- (2012) J. Rosenstock et al. DIABETES CARE
- GLP-1 based therapies: differential effects on fasting and postprandial glucose
- (2012) M.S. Fineman et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
- (2012) Ele Ferrannini et al. Nature Reviews Endocrinology
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Global obesity: trends, risk factors and policy implications
- (2012) Vasanti S. Malik et al. Nature Reviews Endocrinology
- Targeting the glucagon receptor family for diabetes and obesity therapy
- (2012) Young Min Cho et al. PHARMACOLOGY & THERAPEUTICS
- Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
- (2011) J. Dushay et al. DIABETES CARE
- Emerging GLP-1 receptor agonists
- (2011) Asger Lund et al. EXPERT OPINION ON EMERGING DRUGS
- Lixisenatide for type 2 diabetes mellitus
- (2011) Mikkel Christensen et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- GLP-1 Inhibits and Adrenaline Stimulates Glucagon Release by Differential Modulation of N- and L-Type Ca2+ Channel-Dependent Exocytosis
- (2010) Yang Z. De Marinis et al. Cell Metabolism
- The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
- (2010) K. J. Hare et al. DIABETES
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
- (2010) Wolfgang Glaesner et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Bariatric surgery: Mechanisms, indications and outcomes
- (2010) Paul E O'Brien JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The metabolic actions of glucagon revisited
- (2010) Kirk M. Habegger et al. Nature Reviews Endocrinology
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects
- (2009) R E Steinert et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Exenatide once weekly for the treatment of type 2 diabetes
- (2009) James Malone et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
- (2009) Volker Schellenberger et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now